Health Economics Study on Ondine’s Steriwave® Selected for Oral Presentation at ICPIC 2025 in Geneva

Ondine Biomedical Inc. (LON: OBI) announces that it was invited to make an oral presentation about health and economic benefits of Steriwave nasal photodisinfection at the 12th International Conference on Prevention & Infection Control (ICPIC) in Geneva, Switzerland. ICPIC is recognized as the leading conference for infection prevention and control, attracting global experts and healthcare innovators. The Company’s abstract detailing a health economic analysis by the York Health Economics Consortium (YHEC) has been accepted and upgraded to an oral presentation (session O06). The annual global conference will be held 16-19 September 2025, in Geneva, Switzerland.

This presentation will highlight how Steriwave nasal photodisinfection significantly reduces costs associated with surgical site infections (SSIs), demonstrated in both a patient series of elective hip and knee replacements at Mid Yorkshire Teaching NHS Trust (MYTT) and more extensively in two separate health economic models using literature-derived data across multiple surgical specialties. YHEC’s research shows that Steriwave not only improves patient outcomes but also delivers substantial net savings by preventing SSIs in major surgeries.

Simon Sinclair, Chief Medical Officer of Ondine Biomedical said:

"These results are significant for hospital administrators and patients alike, especially with the unprecedented strain on healthcare systems worldwide. Preventing infections is not just about patient safety, it is a critical strategy for conserving resources, improving hospital efficiency, and combating antimicrobial resistance. The Mid Yorkshire data, combined with our rigorous economic modeling, shows how a simple, rapid intervention like Steriwave can have a profound impact on patient outcomes and reduce the economic burden of surgical site infections. This ICPIC recognition underscores Ondine’s ongoing commitment to improving hospital infection control with cost-effective healthcare solutions."

Steriwave is a non-invasive and pain-free nasal decolonisation treatment that uses a proprietary light-activated antimicrobial agent to destroy harmful pathogens—including bacteria, viruses, and fungi—in the nose. Steriwave treatment involves applying a proprietary photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light for five minutes. The treatment is effective immediately, takes less than five minutes, and preserves the natural microbiome while offering immediate microbial reduction without the development of resistance. It is widely used in hospitals across Canada and increasingly in the UK.